Literature DB >> 16162728

Central sleep apnea in stable methadone maintenance treatment patients.

David Wang1, Harry Teichtahl, Olaf Drummer, Cathy Goodman, Gaye Cherry, David Cunnington, Ian Kronborg.   

Abstract

STUDY
OBJECTIVES: Methadone, a long-acting mu-opioid agonist, is an effective treatment for heroin addiction. Our previous data show that 6 of 10 methadone maintenance treatment (MMT) patients had central sleep apnea (CSA). This study aims to confirm these results and to investigate the pathogenesis of the CSA.
METHODS: Twenty-five male and 25 female MMT patients and 20 age-, sex-, and body mass index (BMI)-matched normal subjects were tested with polysomnography, blood toxicology, and ventilatory responses to hypoxia and hypercapnia. Resting cardiorespiratory tests were performed in the MMT group
RESULTS: MMT patients and normal subjects were 35 +/- 9 years old (mean +/- SD), and BMI values were 27 +/- 6 kg/m2 and 27 +/- 5 kg/m2, respectively. Thirty percent of MMT patients had a central apnea index (CAI) > 5, and 20% had a CAI > 10. All normal subjects had a CAI < 1, and no difference was found in obstructive apnea-hypopnea index between the two groups. Methadone blood concentration was the only significant variable (t = 2.33, p = 0.025) associated with CAI and explains 12% of the variance. Awake Pa(CO2), antidepressant use, reduced ventilatory response to hypercapnia, and widened awake alveolar-arterial oxygen pressure gradient together explain a further 17% of the CAI variance.
CONCLUSIONS: Thirty percent of stable MMT patients have CSA, a minority of which can be explained by blood methadone concentration. Other physiologic variables may also play a role in the pathogenesis of CSA in MMT patients, and further research is indicated in this area.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162728     DOI: 10.1378/chest.128.3.1348

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  76 in total

1.  Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment.

Authors:  Stephen R Baldassarri; Mark Beitel; Andrey Zinchuk; Nancy S Redeker; David E Oberleitner; Lindsay M S Oberleitner; Danilo Carrasco; Lynn M Madden; Nathan Lipkind; David A Fiellin; Lori A Bastian; Kevin Chen; H Klar Yaggi; Declan T Barry
Journal:  Sleep Breath       Date:  2020-06-17       Impact factor: 2.816

2.  Positive airway pressure treatment for opioid-related central sleep apnea, where are we now?

Authors:  David Wang; Luke Rowsell; Brendon J Yee
Journal:  Sleep Breath       Date:  2013-10-26       Impact factor: 2.816

3.  Opioid-associated central sleep apnea: a case series.

Authors:  M A Alattar; S M Scharf
Journal:  Sleep Breath       Date:  2008-09-20       Impact factor: 2.816

4.  The quest for stability in an unstable world: adaptive servoventilation in opioid induced complex sleep apnea syndrome.

Authors:  Timothy I Morgenthaler
Journal:  J Clin Sleep Med       Date:  2008-08-15       Impact factor: 4.062

5.  Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort.

Authors:  Lucas M Donovan; Vishesh K Kapur
Journal:  Sleep       Date:  2016-07-01       Impact factor: 5.849

Review 6.  Obstructive sleep apnea and severe mental illness: evolution and consequences.

Authors:  Wei-Chen Lin; John W Winkelman
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

Review 7.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

8.  Adaptive servoventilation for treatment of opioid-associated central sleep apnea.

Authors:  Shahrokh Javaheri; Nicholas Harris; Joseph Howard; Eugene Chung
Journal:  J Clin Sleep Med       Date:  2014-06-15       Impact factor: 4.062

9.  Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy.

Authors:  Jeremiah W Bertz; David H Epstein; David Reamer; William J Kowalczyk; Karran A Phillips; Ashley P Kennedy; Michelle L Jobes; Greg Ward; Barbara A Plitnick; Mariana G Figueiro; Mark S Rea; Kenzie L Preston
Journal:  J Subst Abuse Treat       Date:  2019-08-14

10.  Reversal of central sleep apnea following discontinuation of opioids.

Authors:  Matthew J Davis; Marian Livingston; Steven M Scharf
Journal:  J Clin Sleep Med       Date:  2012-10-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.